Abstract:BACKGROUND:Treatment options for high-risk Brugada syndrome (BrS) with recurrent ventricular fibrillation (VF) are limited. Catheter ablation is increasingly performed but a large study with long-term outcome data is lacking. We report the results of the multicenter, international BRAVO (Brugada Ablation of VF Substrate Ongoing Registry) for treatment of high-risk symptomatic BrS.METHODS:We enrolled 159 patients (median age 42 years; 156 male) with BrS and spontaneous VF in BRAVO; 43 (27%) of them had BrS and early repolarization pattern. All but 5 had an implantable cardioverter-defibrillator for cardiac arrest (n=125) or syncope (n=34). A total of 140 (88%) had experienced numerous implantable cardioverter-defibrillator shocks for spontaneous VF before ablation. All patients underwent a percutaneous epicardial substrate ablation with electroanatomical mapping except for 8 who underwent open-thoracotomy ablation.RESULTS:In all patients, VF/BrS substrates were recorded in the epicardial surface of the right ventricular outflow tract; 45 (29%) patients also had an arrhythmic substrate in the inferior right ventricular epicardium and 3 in the posterior left ventricular epicardium. After a single ablation procedure, 128 of 159 (81%) patients remained free of VF recurrence; this number increased to 153 (96%) after a repeated procedure (mean 1.2±0.5 procedures; median=1), with a mean follow-up period of 48±29 months from the last ablation. VF burden and frequency of shocks decreased significantly from 1.1±2.1 per month before ablation to 0.003±0.14 per month after the last ablation (P<0.0001). The Kaplan-Meier VF-free survival beyond 5 years after the last ablation was 95%. The only variable associated with a VF-free outcome in multivariable analysis was normalization of the type 1 Brugada ECG, both with and without sodium-channel blockade, after the ablation (hazard ratio, 0.078 [95% CI, 0.008 to 0.753]; P=0.0274). There were no arrhythmic or cardiac deaths. Complications included hemopericardium in 4 (2.5%) patients.CONCLUSIONS:Ablation treatment is safe and highly effective in preventing VF recurrence in high-risk BrS. Prospective studies are needed to determine whether it can be an alternative treatment to implantable cardioverter-defibrillator implantation for selected patients with BrS.REGISTRATION:URL: https://www.CLINICALTRIALS:gov; Unique identifier: NCT04420078.

Brugada Syndrome: Anesthetic Implications in an Incidentally Diagnosed Patient

Anesthesiological management of Brugada syndrome patients: A systematic review

Anesthesia in patients with Brugada syndrome: two case reports

Patient-Specific and Genome-Edited Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Brugada Syndrome

Novel Therapeutic Strategies for the Management of Ventricular Arrhythmias Associated with the Brugada Syndrome

Long-Term Outcomes of Brugada Substrate Ablation: A Report from BRAVO (brugada Ablation of VF Substrate Ongoing Multicenter Registry).

Brugada Syndrome: Clinical, Genetic, Molecular, Cellular, and Ionic Aspects

Electrocardiographic Characteristics of Brugada Syndrome Type I During Exercise Stress Test

Patient-specific Ipsc-Derived Cardiomyocytes Reveal Aberrant Activation of Wnt/β-catenin Signaling in SCN5A-related Brugada Syndrome

Brugada Syndrome: Focus for the General Pediatrician

Ablation for the treatment of Brugada syndrome: current status and future prospects

Novelties in Brugada Syndrome: Complex Genetics, Risk Stratification, and Catheter Ablation

Present Status of Brugada Syndrome: JACC State-of-the-Art Review

Simulation of Brugada Syndrome Using Cellular and Three-Dimensional Whole-Heart Modeling Approaches

Brugada Pattern Manifesting During Hyperkalemia, Diabetic Ketoacidosis, and Acute Alcohol Intoxication

High‐risk atrioventricular block in Brugada syndrome patients with a history of syncope

Brugada syndrome: identification of subjects at risk and therapy

Incidence, recurrence and management of electrical storm in Brugada syndrome

Brugada syndrome: current clinical aspects and risk stratification

Prediction and Prevention of Sudden Death in the Brugada Syndrome

Catheter ablation as an adjunctive therapy to ICD implantation in Brugada Syndrome